1. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single‐Arm, Open‐Label Phase IIIb CONSIGN Study.
- Author
-
Van Cutsem, Eric, Martinelli, Erika, Cascinu, Stefano, Sobrero, Alberto, Banzi, Maria, Seitz, Jean‐François, Barone, Carlo, Ychou, Marc, Peeters, Marc, Brenner, Baruch, Hofheinz, Ralf Dieter, Maiello, Evaristo, André, Thierry, Spallanzani, Andrea, Garcia‐Carbonero, Rocio, Arriaga, Yull E., Verma, Udit, Grothey, Axel, Kappeler, Christian, and Miriyala, Ashok
- Subjects
DIARRHEA ,HYPERTENSION risk factors ,LIVER injuries ,FATIGUE risk factors ,HYPOPHOSPHATEMIA ,HAND-foot syndrome ,ASPARTATE aminotransferase ,BILIRUBIN ,CLINICAL trials ,CONFIDENCE intervals ,COLON tumors ,DRUG side effects ,CLINICAL drug trials ,HEALTH services accessibility ,LONGITUDINAL method ,MARKETING ,METASTASIS ,RECTUM tumors ,SURVIVAL ,TERMINATION of treatment ,ALANINE aminotransferase ,TREATMENT effectiveness ,SEVERITY of illness index ,DISEASE progression ,TREATMENT duration ,PROTEIN kinase inhibitors ,PROGNOSIS ,DISEASE risk factors ,THERAPEUTICS - Abstract
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF